ABSTRACT Introduction Etrasimod is an oral sphingosine-1-phosphate receptor modulator approved for the treatment of moderate to severe ulcerative colitis. Its targeted mechanism, once-daily dosing, and oral formulation make it an important addition to the therapeutic landscape. However, its safety profile and optimal clinical positioning require careful evaluation.
Michael Colwill
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack